Abstract Number: 1148 • 2014 ACR/ARHP Annual Meeting
Evaluation of a Methodological Approach to Determine Timing of Rheumatoid Arthritis Disease Onset Using Administrative Claims Data
Background/Purpose: The identification of patients with recent-onset rheumatoid arthritis (RA) is often desirable to create inception cohorts of patients. We evaluated an approach to identify…Abstract Number: 1147 • 2014 ACR/ARHP Annual Meeting
Economic Implications of Flares Among Patients with Early Rheumatoid Arthritis (RA)
Background/Purpose: Government mandated dose tapering and withdrawal of biologic treatments for RA after achievement of sustained disease control is currently observed in Taiwan, the Netherlands,…Abstract Number: 1146 • 2014 ACR/ARHP Annual Meeting
Cost-Effectiveness of Adalimumab for Rheumatoid Arthritis in Germany
Background/Purpose: In Germany, Rheumatoid Arthritis (RA) can be treated with TNF-α inhibitors after the failure of conventional disease-modifying antirheumatic drugs like Methotrexate. The clinical use…Abstract Number: 1145 • 2014 ACR/ARHP Annual Meeting
Evaluation of Biologic Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization Post-Tumor Necrosis Factor Inhibitor Discontinuation in Rheumatoid Arthritis
Background/Purpose: For rheumatoid arthritis (RA) patients (pts) with inadequate response to a TNF inhibitor (TNFi), limited evidence exists from observational studies and indirect comparisons of…Abstract Number: 1144 • 2014 ACR/ARHP Annual Meeting
Economic Implications for Policies Regarding Triple Therapy Use in Patients with Rheumatoid Arthritis
Background/Purpose: Recent randomized controlled trials in rheumatoid arthritis (RA) patients have determined that a strategy of first adding the two Disease Modifying Anti-Rheumatic Drugs (DMARDs)…Abstract Number: 1143 • 2014 ACR/ARHP Annual Meeting
Preferences of Biologic Treatment Characteristics Among Rheumatoid Arthritis Patients Who Are Current Biologic Therapy Users
Background/Purpose: To identify the most and least important characteristics of rheumatoid arthritis (RA) treatment according to patients currently on biologic therapy. Methods: From the HealthCore…Abstract Number: 1142 • 2014 ACR/ARHP Annual Meeting
Healthcare Costs Associated with Serious Infections Among Biologic-Naïve Rheumatoid Arthritis Patients Initiating First-Line Biologic Treatment
Background/Purpose: The risk of serious infections can vary across biologics. For example, in the 2-year AMPLE trial, serious infections occurred in 3.8% of SC abatacept-treated…Abstract Number: 1141 • 2014 ACR/ARHP Annual Meeting
Comparisons of Quality of Life, Resource Use and Physical Functioning in RA Patients Classified As High, Moderate or Low Risk for Rapid Radiographic Progression
Background/Purpose: We developed and validated a prognostic model to identify subjects with elevated risk of rapid radiographic progression (RRP). The objective of this study was…Abstract Number: 1160 • 2014 ACR/ARHP Annual Meeting
Annual Real-Practice Costs of Biologics for 200 Cases with Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Treated By Tight Control and Treat to Target Strategy Permitting Dose Reduction
Background/Purpose To investigate annually real-practice costs of biologic therapy for rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) cohort treated by tight control…Abstract Number: 1138 • 2014 ACR/ARHP Annual Meeting
Vasoactive Intestinal Peptide (VIP) Genetic Variants Determine VIP Serum Levels and Could be Used As a Prognosis Biomarker
Background/Purpose: VIP has shown immunoregulatory properties in assays performed with human or murine cells. VIP has demonstrated a therapeutic effect in a murine model of…Abstract Number: 1137 • 2014 ACR/ARHP Annual Meeting
Multiway Transcriptomic Analysis of Monocyte-Derived Dendritic Cells Discriminates Effects of Disease and of HLA-B27 in Spondyloarthritis
Background/Purpose Spondyloarthritis (SpA) etiology is largely multifactorial with a genetic component dominated by the long-known strong association with the HLA-B27 allele. This allele, however, is…Abstract Number: 1136 • 2014 ACR/ARHP Annual Meeting
Transcriptional Heterogeneity of the SLC2A9 Gene Encoding the GLUT9 Urate Transporter
Background/Purpose: Variation in SLC2A9, which encodes the urate transporter GLUT9, is the major single genetic determinant of serum uric acid (SUA); however, the causal variant(s)…Abstract Number: 1135 • 2014 ACR/ARHP Annual Meeting
Genes Involved in Cartilage Synthesis and Risk to Knee Osteoarthritis
Background/Purpose Osteoarthritis (OA), characterized by gradual loss of articular cartilage in the joint, is a leading cause of disability among the elderly people. Though the…Abstract Number: 1134 • 2014 ACR/ARHP Annual Meeting
Role of NOD2 Pathway in Sarcoidosis Cases with Characteristics of Blau Syndrome
Background/Purpose: Blau syndrome (BS) is a rare autosomal dominant, autoinflammatory syndrome characterized by the clinical triad symptoms of symmetric arthritis, dermatitis, and granulomatous recurrent uveitis,…Abstract Number: 1133 • 2014 ACR/ARHP Annual Meeting
Genetic Variants Influencing Joint Damage in Mexican Americans and European Americans with Rheumatoid Arthritis
Background/Purpose: Joint damage in rheumatoid arthritis (RA) has been shown to be heritable, but knowledge on specific genetic determinants of joint damage in RA is…
ACR Meeting Abstracts